144 related articles for article (PubMed ID: 37209144)
1. Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy.
Pellegrino F; Sjoberg DD; Tin AL; Benfante NE; Briganti A; Montorsi F; Scardino PT; Eastham JA; Vickers AJ; Lilja H; Laudone VP
World J Urol; 2023 Jun; 41(6):1489-1495. PubMed ID: 37209144
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
Assel MJ; Ulmert HD; Karnes RJ; Boorjian SA; Hillman DW; Vickers AJ; Klee GG; Lilja H
Prostate; 2020 Jan; 80(1):51-56. PubMed ID: 31603253
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
4. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
[TBL] [Abstract][Full Text] [Related]
5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
6. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
[TBL] [Abstract][Full Text] [Related]
8. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
9. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
10. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
Bjartell AS; Al-Ahmadie H; Serio AM; Eastham JA; Eggener SE; Fine SW; Udby L; Gerald WL; Vickers AJ; Lilja H; Reuter VE; Scardino PT
Clin Cancer Res; 2007 Jul; 13(14):4130-8. PubMed ID: 17634540
[TBL] [Abstract][Full Text] [Related]
11. Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
Lonergan PE; Cowan JE; Washington SL; Greenberg SA; Nguyen HG; Carroll PR
Prostate; 2021 Sep; 81(13):1009-1017. PubMed ID: 34288004
[TBL] [Abstract][Full Text] [Related]
12. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
15. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
Wenske S; Korets R; Cronin AM; Vickers AJ; Fleisher M; Scher HI; Pettersson K; Guillonneau B; Scardino PT; Eastham JA; Lilja H
Int J Cancer; 2009 Feb; 124(3):659-63. PubMed ID: 19003994
[TBL] [Abstract][Full Text] [Related]
17. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
[TBL] [Abstract][Full Text] [Related]
18. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
[TBL] [Abstract][Full Text] [Related]
19. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
Lilja H; Haese A; Björk T; Friedrich MG; Piironen T; Pettersson K; Huland E; Huland H
J Urol; 1999 Dec; 162(6):2029-34; discussion 2034-5. PubMed ID: 10569562
[TBL] [Abstract][Full Text] [Related]
20. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]